{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:42:38Z","timestamp":1762087358101,"version":"build-2065373602"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":109,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Diabetes mellitus ist h\u00e4ufig mit psychischen Erkrankungen assoziiert. Depressive St\u00f6rungen kommen bei diabetischen Patient:innen doppelt so h\u00e4ufig vor wie in der nicht-diabetischen Population. Andere psychische Erkrankungen, die geh\u00e4uft mit Pr\u00e4diabetes und Diabetes mellitus vorkommen, sind kognitive Dysfunktionen bis zur Demenz, auff\u00e4lliges Essverhalten, Angstst\u00f6rungen, Schizophrenie, bipolare St\u00f6rungen und Borderline-Pers\u00f6nlichkeitsst\u00f6rungen. Die ung\u00fcnstigen Auswirkungen dieser Koinzidenz auf den Stoffwechsel sind nachhaltig und manifestieren als schlechtere metabolische Kontrolle und vermehrte mikro- und makroangiopathische Komplikationen. Ziel dieses Positionspapieres ist die Sensibilisierung aller involvierten medizinischen Fachkolleg:innen sowie aller anderen mit dem Thema Diabetes befassten Berufsgruppen und Organisationen, um eine Intensivierung der komplexen therapeutischen Interventionen bei Patient:innen zu erreichen.<\/jats:p><jats:p>Positive Auswirkungen w\u00e4ren die Verringerung der Inzidenz von Diabetes mellitus bei Patient:innen mit psychischen Erkrankungen, sowie die Reduktion von Sp\u00e4tfolgen des Diabetes mellitus, insbesondere der kardiovaskul\u00e4ren Morbidit\u00e4t und Mortalit\u00e4t und eine verbesserte Lebensqualit\u00e4t der Betroffenen.<\/jats:p>","DOI":"10.1007\/s00508-022-02117-9","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:03:25Z","timestamp":1682550205000},"page":"225-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Psychische und neurokognitive Erkrankungen und Diabetes mellitus (Update 2023)","Mental disorders and diabetes mellitus (Update 2023)"],"prefix":"10.1007","volume":"135","author":[{"given":"Heidemarie","family":"Abrahamian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kautzky-Willer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Rie\u00dfland-Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Lebherz-Eichinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Ebenbichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kautzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Toplak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"12","key":"2117_CR1","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.2337\/dc16-2053","volume":"39","author":"D Young-Hyman","year":"2016","unstructured":"Young-Hyman\u00a0D, de Groot\u00a0M, Hill-Briggs\u00a0F, et al. Psychosocial care for people with diabetes: a position statement of the American diabetes association. Diabetes Care. 2016;39(12):2126\u201340. https:\/\/doi.org\/10.2337\/dc16-2053.","journal-title":"Diabetes Care"},{"issue":"3","key":"2117_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","volume":"26","author":"M De Hert","year":"2011","unstructured":"De Hert\u00a0M, Dobbelaere\u00a0M, Sheridan\u00a0EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144\u201358. https:\/\/doi.org\/10.1016\/j.eurpsy.2010.09.011.","journal-title":"Eur Psychiatry"},{"issue":"6","key":"2117_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","volume":"192","author":"M Smith","year":"2008","unstructured":"Smith\u00a0M, Hopkins\u00a0D, Peveler\u00a0RC, et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406\u201311. https:\/\/doi.org\/10.1192\/bjp.bp.107.037184.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"2117_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","volume":"24","author":"M De Hert","year":"2009","unstructured":"De Hert\u00a0M, Dekker\u00a0JM, Wood\u00a0D, et\u00a0al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European psychiatric association (EPA), supported by the European association for the study of diabetes (EASD) and the European society of cardiology (ESC). Eur Psychiatry. 2009;24(6):412\u201324.","journal-title":"Eur Psychiatry"},{"key":"2117_CR5","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1995","author":"Today Study Group","year":"2022","unstructured":"Today Study Group. Longitudinal association of depressive symptoms, binge eating, and quality of life with cardiovascular risk factors in young adults with youth-onset type 2 diabetes: the TODAY2 study. Diabetes Care. 2022; https:\/\/doi.org\/10.2337\/dc21-1995.","journal-title":"Diabetes Care"},{"issue":"2","key":"2117_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2337\/dc11-1572","volume":"35","author":"L Fisher","year":"2012","unstructured":"Fisher\u00a0L, Hessler\u00a0DM, Polonsky\u00a0WH, et\u00a0al. When is diabetes distress clinically meaningful?: establishing cut points for the diabetes distress scale. Diabetes Care. 2012;35(2):259\u201364. https:\/\/doi.org\/10.2337\/dc11-1572.","journal-title":"Diabetes Care"},{"key":"2117_CR7","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc15-S007","volume":"38","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. (4) Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care, and immunization. Diabetes Care. 2015;38:S20\u201330. https:\/\/doi.org\/10.2337\/dc15-S007.","journal-title":"Diabetes Care"},{"issue":"1","key":"2117_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1464-5491.2003.00832.x","volume":"20","author":"G Welch","year":"2003","unstructured":"Welch\u00a0G, Weinger\u00a0K, Anderson\u00a0B, et\u00a0al. Responsiveness of the problem areas in diabetes (PAID) questionnaire. Diabet Med. 2003;20(1):69\u201372. https:\/\/doi.org\/10.1046\/j.1464-5491.2003.00832.x.","journal-title":"Diabet Med"},{"issue":"3","key":"2117_CR9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2337\/diacare.28.3.626","volume":"28","author":"WH Polonsky","year":"2005","unstructured":"Polonsky\u00a0WH, Fisher\u00a0L, Earles\u00a0J, et\u00a0al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28(3):626\u201331. https:\/\/doi.org\/10.2337\/diacare.28.3.626.","journal-title":"Diabetes Care"},{"issue":"10","key":"2117_CR10","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s11606-008-0731-9","volume":"23","author":"W Katon","year":"2008","unstructured":"Katon\u00a0W, Fan\u00a0MY, Un\u00fctzer\u00a0J, et\u00a0al. Depression and diabetes: a\u00a0potentially lethal combination. J\u00a0Gen Intern Med. 2008;23(10):1571\u20135. https:\/\/doi.org\/10.1007\/s11606-008-0731-9.","journal-title":"J Gen Intern Med"},{"issue":"8","key":"2117_CR11","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.2337\/dc11-1791","volume":"35","author":"MD Sullivan","year":"2012","unstructured":"Sullivan\u00a0MD, O\u2019Connor\u00a0P, Feeney\u00a0P, et al. Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care. 2012;35(8):1708\u201315. https:\/\/doi.org\/10.2337\/dc11-1791.","journal-title":"Diabetes Care"},{"issue":"6","key":"2117_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2337\/diacare.24.6.1069","volume":"24","author":"RJ Anderson","year":"2001","unstructured":"Anderson\u00a0RJ, Freedland\u00a0KE, Clouse\u00a0RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069\u201378.","journal-title":"Diabetes Care"},{"key":"2117_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/ndt.s5421","volume":"5","author":"H Abrahamian","year":"2009","unstructured":"Abrahamian\u00a0H, Hofmann\u00a0P, Prager\u00a0R, et al. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat. 2009;5:261\u20136. https:\/\/doi.org\/10.2147\/ndt.s5421.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"2117_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00125-006-0159-x","volume":"49","author":"MJ Knol","year":"2006","unstructured":"Knol\u00a0MJ, Twisk\u00a0JW, Beekman\u00a0AT, et al. Depression as a\u00a0risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49(5):837\u201345. https:\/\/doi.org\/10.1007\/s00125-006-0159-x.","journal-title":"Diabetologia"},{"issue":"11","key":"2117_CR15","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1464-5491.2006.01943.x","volume":"23","author":"S Ali","year":"2006","unstructured":"Ali\u00a0S, Stone\u00a0MA, Peters\u00a0JL, et al. The prevalence of co-morbid depression in adults with Type 2 diabetes: a\u00a0systematic review and meta-analysis. Diabet Med. 2006;23(11):1165\u201373. https:\/\/doi.org\/10.1111\/j.1464-5491.2006.01943.x.","journal-title":"Diabet Med"},{"issue":"8","key":"2117_CR16","doi-asserted-by":"publisher","first-page":"e71583","DOI":"10.1371\/journal.pone.0071583","volume":"8","author":"M Franciosi","year":"2013","unstructured":"Franciosi\u00a0M, Lucisano\u00a0G, Lapice\u00a0E, et\u00a0al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583. https:\/\/doi.org\/10.1371\/journal.pone.0071583.","journal-title":"PLoS One"},{"issue":"10","key":"2117_CR17","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s00125-008-1113-x","volume":"51","author":"JS Gonzalez","year":"2008","unstructured":"Gonzalez\u00a0JS, Delahanty\u00a0LM, Safren\u00a0SA, et al. Differentiating symptoms of depression from diabetes-specific distress: relationships with self-care in type 2 diabetes. Diabetologia. 2008;51(10):1822\u20135.","journal-title":"Diabetologia"},{"issue":"7","key":"2117_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1046\/j.1525-1497.1997.00076.x","volume":"12","author":"MA Whooley","year":"1997","unstructured":"Whooley\u00a0MA, Avins\u00a0AL, Miranda\u00a0J, et al. Case-finding instruments for depression. Two questions are as good as many. J\u00a0Gen Intern Med. 1997;12(7):439\u201345. https:\/\/doi.org\/10.1046\/j.1525-1497.1997.00076.x.","journal-title":"J Gen Intern Med"},{"key":"2117_CR19","volume-title":"Beck Depressions-Inventar (BDI-II). Revision","author":"M Hautzinger","year":"2006","unstructured":"Hautzinger\u00a0M, Keller\u00a0F, K\u00fchner\u00a0C. Beck Depressions-Inventar (BDI-II). Revision. Frankfurt am Main: Harcourt Test Services; 2006."},{"key":"2117_CR20","volume-title":"HADS-D. Hospital anxiety and depression scale","author":"C Herrmann-Lingen","year":"2011","unstructured":"Herrmann-Lingen\u00a0C, Buss\u00a0U, Snaith\u00a0RP. HADS\u2011D. Hospital anxiety and depression scale. 3.\u00a0Aufl. Bern: Huber; 2011. Deutsche Version.","edition":"3"},{"issue":"2","key":"2117_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1176\/appi.focus.20150040","volume":"14","author":"JM Gregory","year":"2016","unstructured":"Gregory\u00a0JM, Rosenblat\u00a0JD, McIntyre\u00a0RS. Deconstructing diabetes and depression: clinical context, treatment strategies, and new directions. Focus (Am Psychiatr Publ). 2016;14(2):184\u201393. https:\/\/doi.org\/10.1176\/appi.focus.20150040.","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"6","key":"2117_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2213-8587(15)00045-5","volume":"3","author":"F Petrak","year":"2015","unstructured":"Petrak\u00a0F, Baumeister\u00a0H, Skinner\u00a0TC, et al. Depression and diabetes: treatment and health-care delivery. Lancet Diabetes Endocrinol. 2015;3(6):472\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(15)00045-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10128","key":"2117_CR23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani\u00a0A, Furukawa\u00a0TA, Salanti\u00a0G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a\u00a0systematic review and network meta-analysis. Lancet. 2018;391(10128):1357\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(17)32802-7.","journal-title":"Lancet"},{"issue":"5","key":"2117_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/15622975.2017.1379609","volume":"19","author":"S Dodd","year":"2018","unstructured":"Dodd\u00a0S, Mitchell\u00a0PB, Bauer\u00a0M, et al. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: an international consensus statement. World J Biol Psychiatry. 2018;19(5):330\u201348. https:\/\/doi.org\/10.1080\/15622975.2017.1379609.","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"2117_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","volume":"14","author":"CU Correll","year":"2015","unstructured":"Correll\u00a0CU, Detraux\u00a0J, De Lepeleire\u00a0J, et\u00a0al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119\u201336. https:\/\/doi.org\/10.1002\/wps.20204.","journal-title":"World Psychiatry"},{"issue":"3","key":"2117_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1017\/S1092852913000060","volume":"18","author":"K Demyttenaere","year":"2013","unstructured":"Demyttenaere\u00a0K, Corruble\u00a0E, Hale\u00a0A, et\u00a0al. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr. 2013;18(3):163\u201370. https:\/\/doi.org\/10.1017\/S1092852913000060.","journal-title":"CNS Spectr"},{"issue":"10","key":"2117_CR27","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2174\/1871527313666141130204031","volume":"13","author":"CS Liu","year":"2014","unstructured":"Liu\u00a0CS, Carvalho\u00a0AF, McIntyre\u00a0RS. Towards a\u00a0\u201emetabolic\u201c subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets. 2014;13(10):1693\u2013707. https:\/\/doi.org\/10.2174\/1871527313666141130204031.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"6","key":"2117_CR28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.psyneuen.2012.08.010","volume":"38","author":"L Kashani","year":"2013","unstructured":"Kashani\u00a0L, Omidvar\u00a0T, Farazmand\u00a0B, et al. Does pioglitazone improve depression through insulin-sensitization? Results of a\u00a0randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 2013;38(6):767\u201376. https:\/\/doi.org\/10.1016\/j.psyneuen.2012.08.010.","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"2117_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S2213-8587(13)70139-6","volume":"2","author":"AG Tabak","year":"2014","unstructured":"Tabak\u00a0AG, Akbaraly\u00a0TN, Batty\u00a0GD, et\u00a0al. Depression and type 2 diabetes: a\u00a0causal association? Lancet Diabetes Endocrinol. 2014;2(3):236\u201345. https:\/\/doi.org\/10.1016\/S2213-8587(13)70139-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2117_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/DMSO.S106797","volume":"11","author":"L Darwish","year":"2018","unstructured":"Darwish\u00a0L, Beroncal\u00a0E, Sison\u00a0MV, et\u00a0al. Depression in people with type 2 diabetes: current perspectives. Diabetes Metab Syndr Obes. 2018;11:333\u201343. https:\/\/doi.org\/10.2147\/DMSO.S106797.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"21","key":"2117_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10354-011-0004-9","volume":"161","author":"C Ress","year":"2011","unstructured":"Ress\u00a0C, Tschoner\u00a0A, Kaser\u00a0S, et\u00a0al. Psychopharmaka und Diabetes. Wien Med Wochenschr. 2011;161(21):531\u201342. https:\/\/doi.org\/10.1007\/s10354-011-0004-9.","journal-title":"Wien Med Wochenschr"},{"issue":"2","key":"2117_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1464-5491.2008.02648.x","volume":"26","author":"MM Collins","year":"2009","unstructured":"Collins\u00a0MM, Corcoran\u00a0P, Perry\u00a0IJ. Anxiety and depression symptoms in patients with diabetes. Diabet Med. 2009;26(2):153\u201361. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02648.x.","journal-title":"Diabet Med"},{"issue":"6","key":"2117_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.genhosppsych.2006.08.004","volume":"28","author":"E Ludman","year":"2006","unstructured":"Ludman\u00a0E, Katon\u00a0W, Russo\u00a0J, et\u00a0al. Panic episodes among patients with diabetes. Gen Hosp Psychiatry. 2006;28(6):475\u201381. https:\/\/doi.org\/10.1016\/j.genhosppsych.2006.08.004.","journal-title":"Gen Hosp Psychiatry"},{"issue":"3","key":"2117_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2337\/dc08-1077","volume":"33","author":"DL Young-Hyman","year":"2010","unstructured":"Young-Hyman\u00a0DL, Davis\u00a0CL. Disordered eating behavior in individuals with diabetes: importance of context, evaluation, and classification. Diabetes Care. 2010;33(3):683\u20139. https:\/\/doi.org\/10.2337\/dc08-1077.","journal-title":"Diabetes Care"},{"issue":"3","key":"2117_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2337\/dc09-1890","volume":"33","author":"JT Markowitz","year":"2010","unstructured":"Markowitz\u00a0JT, Butler\u00a0DA, Volkening\u00a0LK, et\u00a0al. Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a\u00a0contemporary sample of pediatric patients with type 1 diabetes. Diabetes Care. 2010;33(3):495\u2013500. https:\/\/doi.org\/10.2337\/dc09-1890.","journal-title":"Diabetes Care"},{"issue":"3","key":"2117_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00406-012-0339-2","volume":"263","author":"KG Kahl","year":"2013","unstructured":"Kahl\u00a0KG, Greggersen\u00a0W, Schweiger\u00a0U, et al. Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a\u00a0cross-sectional study. Eur Arch Psychiatry Clin Neurosci. 2013;263(3):205\u201313. https:\/\/doi.org\/10.1007\/s00406-012-0339-2.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2117_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1741-7015-9-118","volume":"9","author":"Q Mai","year":"2011","unstructured":"Mai\u00a0Q, Holman\u00a0CD, Sanfilippo\u00a0FM, et al. Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a\u00a0population-based longitudinal study. BMC Med. 2011;9:118. https:\/\/doi.org\/10.1186\/1741-7015-9-118.","journal-title":"BMC Med"},{"issue":"1","key":"2117_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","volume":"80","author":"DC Goff","year":"2005","unstructured":"Goff\u00a0DC, Sullivan\u00a0LM, McEvoy\u00a0JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45\u201353. https:\/\/doi.org\/10.1016\/j.schres.2005.08.010.","journal-title":"Schizophr Res"},{"issue":"1","key":"2117_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3371\/CSRP.5.1.5","volume":"5","author":"BJ Jones","year":"2011","unstructured":"Jones\u00a0BJ, Gallagher\u00a0BJ, Moss\u00a0DM, et\u00a0al. Obstetrical complications, social class and type of schizophrenia. Clin Schizophr Relat Psychoses. 2011;5(1):33\u20139. https:\/\/doi.org\/10.3371\/CSRP.5.1.5.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"12","key":"2117_CR40","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.psyneuen.2012.04.001","volume":"37","author":"W Beumer","year":"2012","unstructured":"Beumer\u00a0W, Drexhage\u00a0RC, De Wit\u00a0H, et\u00a0al. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37(12):1901\u201311. https:\/\/doi.org\/10.1016\/j.psyneuen.2012.04.001.","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"2117_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/ijnp\/pyaa097","volume":"24","author":"Y Mizuki","year":"2021","unstructured":"Mizuki\u00a0Y, Sakamoto\u00a0S, Okahisa\u00a0Y, et\u00a0al. Mechanisms underlying the comorbidity of schizophrenia and type 2 diabetes mellitus. Int J Neuropsychopharmacol. 2021;24(5):367\u201382. https:\/\/doi.org\/10.1093\/ijnp\/pyaa097.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"2117_CR42","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","volume":"48","author":"T Cukierman","year":"2005","unstructured":"Cukierman\u00a0T, Gerstein\u00a0HC, Williamson\u00a0JD. Cognitive decline and dementia in diabetes\u2014systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460\u20139. https:\/\/doi.org\/10.1007\/s00125-005-0023-4.","journal-title":"Diabetologia"},{"issue":"1","key":"2117_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/db09-1600","volume":"59","author":"ER Seaquist","year":"2010","unstructured":"Seaquist\u00a0ER. The final frontier: how does diabetes affect the brain? Diabetes. 2010;59(1):4\u20135. https:\/\/doi.org\/10.2337\/db09-1600.","journal-title":"Diabetes"},{"issue":"18","key":"2117_CR44","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1056\/NEJMoa066397","volume":"356","author":"AM Jacobson","year":"2007","unstructured":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Study Research Group, Jacobson\u00a0AM, Musen\u00a0G, et al. Long-term effect of diabetes and its treatment on cognitive function. N\u00a0Engl J Med. 2007;356(18):1842\u201352. https:\/\/doi.org\/10.1056\/NEJMoa066397.","journal-title":"N Engl J Med"},{"issue":"1","key":"2117_CR45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2337\/db09-1117","volume":"59","author":"T Hershey","year":"2010","unstructured":"Hershey\u00a0T, Perantie\u00a0DC, Wu\u00a0J, et\u00a0al. Hippocampal volumes in youth with type 1 diabetes. Diabetes. 2010;59(1):236\u201341. https:\/\/doi.org\/10.2337\/db09-1117.","journal-title":"Diabetes"},{"issue":"11","key":"2117_CR46","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1474-4422(11)70188-0","volume":"10","author":"LJ Launer","year":"2011","unstructured":"Launer\u00a0LJ, Miller\u00a0ME, Williamson\u00a0JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a\u00a0randomised open-label substudy. Lancet Neurol. 2011;10(11):969\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(11)70188-0.","journal-title":"Lancet Neurol"},{"issue":"11","key":"2117_CR47","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.4088\/JCP.v68n1107","volume":"68","author":"CJ Bushe","year":"2007","unstructured":"Bushe\u00a0CJ, Leonard\u00a0BE. Blood glucose and schizophrenia: a\u00a0systematic review of prospective randomized clinical trials. J\u00a0Clin Psychiatry. 2007;68(11):1682\u201390.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2117_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/dia.2010.0092","volume":"13","author":"JJ Prisciandaro","year":"2011","unstructured":"Prisciandaro\u00a0JJ, Gebregziabher\u00a0M, Grubaugh\u00a0AL, et\u00a0al. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes. Diabetes Technol Ther. 2011;13(1):73\u20138. https:\/\/doi.org\/10.1089\/dia.2010.0092.","journal-title":"Diabetes Technol Ther"},{"key":"2117_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1192\/bjp.184.1.58","volume":"184","author":"ZJ Zhang","year":"2004","unstructured":"Zhang\u00a0ZJ, Yao\u00a0ZJ, Liu\u00a0W, et\u00a0al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58\u201362. https:\/\/doi.org\/10.1192\/bjp.184.1.58.","journal-title":"Br J Psychiatry"},{"issue":"13","key":"2117_CR50","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1001\/jama.284.13.1709-JMS1004-6-1","volume":"284","author":"MM Funnell","year":"2000","unstructured":"Funnell\u00a0MM, Anderson\u00a0RM. The problem with compliance in diabetes. JAMA. 2000;284(13):1709.","journal-title":"JAMA"},{"issue":"2","key":"2117_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2337\/diaclin.24.2.71","volume":"24","author":"AM Delamater","year":"2006","unstructured":"Delamater\u00a0AM. Improving patient adherence. Clin Diabetes. 2006;24(2):71\u20137. https:\/\/doi.org\/10.2337\/diaclin.24.2.71.","journal-title":"Clin Diabetes"},{"issue":"3","key":"2117_CR52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2337\/diacare.24.3.561","volume":"24","author":"SL Norris","year":"2001","unstructured":"Norris\u00a0SL, Engelgau\u00a0MM, Narayan\u00a0KM. Effectiveness of self-management training in type 2 diabetes: a\u00a0systematic review of randomized controlled trials. Diabetes Care. 2001;24(3):561\u201387. https:\/\/doi.org\/10.2337\/diacare.24.3.561.","journal-title":"Diabetes Care"},{"issue":"9","key":"2117_CR53","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/jme.2005.012138","volume":"32","author":"JS Chatterjee","year":"2006","unstructured":"Chatterjee\u00a0JS. From compliance to concordance in diabetes. J\u00a0Med Ethics. 2006;32(9):507\u201310. https:\/\/doi.org\/10.1136\/jme.2005.012138.","journal-title":"J Med Ethics"},{"issue":"7442","key":"2117_CR54","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/bmj.328.7442.741","volume":"328","author":"SE Roberts","year":"2004","unstructured":"Roberts\u00a0SE, Goldacre\u00a0MJ, Neil\u00a0HA. Mortality in young people admitted to hospital for diabetes: database study. BMJ. 2004;328(7442):741\u20132. https:\/\/doi.org\/10.1136\/bmj.328.7442.741.","journal-title":"BMJ"},{"issue":"2","key":"2117_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5414\/cpp44051","volume":"44","author":"MA von Mach","year":"2006","unstructured":"von Mach\u00a0MA, Gauer\u00a0M, Meyer\u00a0S, et\u00a0al. Antidiabetic medications in overdose: a\u00a0comparison of the inquiries made to a\u00a0regional poisons unit regarding original sulfonylureas, biguanides and insulin. Int J Clin Pharmacol Ther. 2006;44(2):51\u20136. https:\/\/doi.org\/10.5414\/cpp44051.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"2117_CR56","doi-asserted-by":"publisher","first-page":"613","DOI":"10.7326\/0003-4819-129-8-199810150-00005","volume":"129","author":"PJ Lustman","year":"1998","unstructured":"Lustman\u00a0PJ, Griffith\u00a0LS, Freedland\u00a0KE, et\u00a0al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;129(8):613\u201321. https:\/\/doi.org\/10.7326\/0003-4819-129-8-199810150-00005.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2117_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1370\/afm.1344","volume":"10","author":"HR Bogner","year":"2012","unstructured":"Bogner\u00a0HR, Morales\u00a0KH, de Vries\u00a0HF, et\u00a0al. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a\u00a0randomized controlled trial. Ann Fam Med. 2012;10(1):15\u201322. https:\/\/doi.org\/10.1370\/afm.1344.","journal-title":"Ann Fam Med"},{"issue":"1","key":"2117_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psym.2010.11.007","volume":"52","author":"SM Markowitz","year":"2011","unstructured":"Markowitz\u00a0SM, Gonzalez\u00a0JS, Wilkinson\u00a0JL, et\u00a0al. A review of treating depression in diabetes: emerging findings. Psychosomatics. 2011;52(1):1\u201318. https:\/\/doi.org\/10.1016\/j.psym.2010.11.007.","journal-title":"Psychosomatics"},{"issue":"3","key":"2117_CR59","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PSY.0b013e318042588d","volume":"69","author":"A Georgiades","year":"2007","unstructured":"Georgiades\u00a0A, Zucker\u00a0N, Friedman\u00a0KE, et\u00a0al. Changes in depressive symptoms and glycemic control in diabetes mellitus. Psychosom Med. 2007;69(3):235\u201341. https:\/\/doi.org\/10.1097\/PSY.0b013e318042588d.","journal-title":"Psychosom Med"},{"issue":"1","key":"2117_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0738-3991(02)00213-6","volume":"51","author":"L Steed","year":"2003","unstructured":"Steed\u00a0L, Cooke\u00a0D, Newman\u00a0S. A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus. Patient Educ Couns. 2003;51(1):5\u201315. https:\/\/doi.org\/10.1016\/s0738-3991(02)00213-6.","journal-title":"Patient Educ Couns"},{"issue":"19","key":"2117_CR61","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1111\/j.1365-2702.2008.02301.x","volume":"17","author":"MY Wang","year":"2008","unstructured":"Wang\u00a0MY, Tsai\u00a0PS, Chou\u00a0KR, et al. A systematic review of the efficacy of non-pharmacological treatments for depression on glycaemic control in type 2 diabetics. J\u00a0Clin Nurs. 2008;17(19):2524\u201330. https:\/\/doi.org\/10.1111\/j.1365-2702.2008.02301.x.","journal-title":"J Clin Nurs"},{"issue":"10","key":"2117_CR62","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","volume":"64","author":"S Saha","year":"2007","unstructured":"Saha\u00a0S, Chant\u00a0D, McGrath\u00a0J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123\u201331. https:\/\/doi.org\/10.1001\/archpsyc.64.10.1123.","journal-title":"Arch Gen Psychiatry"},{"key":"2117_CR63","unstructured":"National Institute for Health and Care Excellence. Schizophrenia: core intervention in the treatment and management of schizophrenia in adults in primary and secondary care. 2008. http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=download&o=42139. Zugegriffen: 12. Aug. 2015."},{"issue":"4","key":"2117_CR64","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/dom.13167","volume":"20","author":"DJ Siskind","year":"2018","unstructured":"Siskind\u00a0DJ, Russell\u00a0AW, Gamble\u00a0C, Winckel\u00a0K, Mayfield\u00a0K, Hollingworth\u00a0S, et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a\u00a0randomized controlled trial (CODEX). Diabetes Obes Metab. 2018;20(4):1050\u20135.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2117_CR65","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen\u00a0JR, Vedtofte\u00a0L, Jakobsen\u00a0MSL, Jespersen\u00a0HR, Jakobsen\u00a0MI, Svensson\u00a0CK, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum: a\u00a0randomized clinical trial. JAMA Psychiatry. 2017;74(7):719\u201328.","journal-title":"JAMA Psychiatry"},{"key":"2117_CR66","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11892-019-1220-8","volume":"19","author":"RIG Holt","year":"2019","unstructured":"Holt\u00a0RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019;19:96. https:\/\/doi.org\/10.1007\/s11892-019-1220-8.","journal-title":"Curr Diab Rep"},{"key":"2117_CR67","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j-ajem.2021.02.015","volume":"44","author":"B Long","year":"2021","unstructured":"Long\u00a0B, Lentz\u00a0S, Koyfman\u00a0A, Gottlieb\u00a0M. Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med. 2021;44:157\u201360. https:\/\/doi.org\/10.1016\/j-ajem.2021.02.015.","journal-title":"Am J Emerg Med"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-022-02117-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:08:35Z","timestamp":1682550515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-022-02117-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":67,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["2117"],"URL":"https:\/\/doi.org\/10.1007\/s00508-022-02117-9","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"9 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.\u00a0Abrahamian hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, Boehringer Ingelheim, Novo Nordisk, sanofi-aventis, Servier. Zus\u00e4tzlich gibt H.\u00a0Abrahamian an, dass f\u00fcr sie pers\u00f6nlich kein Interessenkonflikt vorliegt. A.\u00a0Kautzky-Willer hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Bayer Health Care, B\u00f6ehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis. A.\u00a0Rie\u00dfland-Seifert hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck. P.\u00a0Fasching hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, AstraZeneca, Bayer Health Care, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Germania Pharmazeutika, GlaxoSmithKline Pharma, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche, sanofi-aventis, Servier, Takeda. Zus\u00e4tzlich gibt P.\u00a0Fasching an, dass f\u00fcr ihn pers\u00f6nlich kein Interessenkonflikt vorliegt. Er legt offen, dass er in diesem Zeitraum von den genannten Firmen Honorare f\u00fcr Vortr\u00e4ge und Consulting erhalten hat bzw. Fortbildungsunterst\u00fctzung im Rahmen der (dienst)rechtlichen Rahmenbedingungen bezogen hat (Einladung zu Kongressen) bzw. Klinische Studien als PI mit einzelnen Firmen durchgef\u00fchrt hat bzw. durchf\u00fchrt. C.\u00a0Ebenbichler hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Boehringer Ingelheim, Novartis, Novo Nordisk, Sanofi-aventis. H.\u00a0Toplak hat von folgenden Unternehmen, die teilweise f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lillly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi-aventis. A.\u00a0Kautzky und D.\u00a0Lebherz-Eichinger geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}